Skip to main content
. 2020 Jan 20;10:641. doi: 10.1038/s41598-020-57496-8

Table 1.

Clinico-pathological characteristics of the 1770 patients.

RTb (+) (n = 1317) RT (−) (n = 453) p*
Age at diagnosisa <50 701 (53.2%) 177 (39.1%) <0.001
≥50 616 (46.8%) 276 (60.9%)
ER Negative 420 (32.3%) 170 (37.9%) 0.032
Positive 882 (67.7%) 278 (62.1%)
PR Negative 575 (44.2%) 245 (54.7%) <0.001
Positive 726 (55.8%) 203 (45.3%)
HER2 Negative 966 (76.3%) 279 (64.6%) <0.001
Positive 300 (23.7%) 153 (35.4%)
p-S6K1 Negative 319 (24.2%) 128 (28.3%) 0.091
Positive 998 (75.8%) 325 (71.7%)
Mass size <2 cm 779 (59.1%) 258 (57.0%) 0.439
≥2 cm 538 (40.9%) 195 (43.0%)
Node status Negative 792 (60.5%) 243 (54.0%) 0.017
Positive 518 (39.5%) 207 (46.0%)
Histology IDC 1134 (86.1%) 395 (87.2%) 0.830
ILC 59 (4.5%) 19 (4.2%)
Others 124 (9.4%) 39 (8.6%)
Histologic grade G1,2 777 (65.8%) 264 (65.2%) 0.427
G3 403 (34.2%) 141(34.8%)
Surgery Breast conserving 1044(79.3%) 26(5.7%) <0.001
Total mastectomy 273(20.7%) 427(94.3%)
Loco-regional recurrence Negative 1279 (97.1%) 432 (95.4%) 0.094
Positive 38 (2.9%) 21 (4.6%)
Biologic subtype Luminal A 746 (59.5%) 206 (48.6%) <0.001
Luminal B 168 (13.4%) 73 (17.1%)
HER2 130 (10.4%) 79 (18.5%)
Triple negative 209 (16.7%) 69 (16.2%)

aFrequency (%).

bRadiotherapy.

*Pearson’s chi-square test and Fisher’s exact test.